유럽, 미국 등 세계 곳곳 코로나 19 재확산 속 백신 치료제 잇따른 중단
Meanwhile, countries in Europe and the U.S. are seeing a Covid-19 resurgence after a brief slowdown in cases from their peak early this year.
The UK has seen over one hundred deaths in a single day - a first in four months, and Italy has imposed stricter quarantine measures to contain a recent spike.
The seven-day average of new infections in the U.S. has also topped 50-thousand for the first time since August.
Amid of all this, vaccine development is seeing another series of delays.
Lee Kyung-eun with the latest.
Europe is once again emerging as the global COVID-19 hotbed,... reporting more daily infections than the U.S., Brazil or India.
Among the hardest hit in the region is the UK.
On Tuesday, it reported over 17-thousand new cases and 1-hundred-43 deaths the first time in four months that deaths have been in triple digits.
Italy is also grappling with a resurgence of the virus.
Weddings and other family-to-family transmissions are at the center of the spread, causing 77 percent of last week's cases.
The Italian Prime Minister, in response, signed a new decree on Monday,...which includes a ban on all parties both indoors and outdoors and early closing times for restaurants.
Meanwhile, the U.S. is already witnessing signs of a second wave.
Top infectious disease expert Dr. Peter Hotez told CNN,.. "This is the fall/winter surge that everyone was worried about. And it's going to be nationally soon enough."
He cited how the country went down to around 30-thousand cases a day in September,... but it's now back up to 50-thousand a day.
Vaccines and treatments for COVID-19 have also hit some pitfalls. On Monday, U.S. drugmaker Johnson and Johnson paused its late-stage clinical trials due to an unexplained illness.
And the next day, another American company Eli Lilly put on hold its antibody treatment for safety reasons.
That's the type of experimental drug President Trump received as part of his COVID-19 treatment.
Currently, 10 vaccine candidates have reached phase three trials, but the WHO expects it to take several months for any of them to be approved.
"So, the best that we could make a guess or predict looking at when a trial started and when it is likely to have enough data to submit to the regulators is the earliest is starting from December of 2020 into the early part of 2021."
Lee Kyung-eun, Arirang News.
